Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
SEATTLE, Oct. 8, 2020 /PRNewswire/ -- Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the appointment of Mark Litton, PhD, MBA, Chief Operating Officer of Athira Pharma (NASDAQ:ATHA), to the company's Board of Directors.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Dr. Litton is an experienced leader in the life sciences industry with a career spanning more than two decades of executive level leadership including as co-founder, Chief Business Officer, and Treasurer of Alder BioPharmaceuticals.
"Mark's extensive expertise in the strategic growth, financing, and development of life science companies will be invaluable to Lumen Bio as we continue to develop Lumen's board and management expertise for the next phase of commercial development," said Brian Finrow, Lumen's co-founder and CEO. "Mark shares our mission-oriented perspective and deep respect for high-quality corporate governance, and we're excited to welcome his independent voice to the Lumen boardroom."
"Lumen Bioscience is pioneering novel drug discovery and production technologies that have the potential to broadly impact many devastating diseases," said Dr. Litton. "I look forward to working with the team as they continue to advance their unique drug development platform."
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
At Athira, Dr. Litton has helped direct the company's Series B and initial public offering. During his tenure at Alder, he led the company's business operations and played a key role in the company's IPO, follow-on financings, collaborations, and partnerships. Prior to Alder, Dr. Litton held executive leadership roles at Celltech Group, Chiroscience Group plc, and Ribozyme. Dr. Litton holds a PhD in Immunology from Stockholm University, an MBA from Santa Clara University, and a BS in Biochemistry from the University of California, Santa Cruz.
About Lumen
Lumen Bioscience discovers, develops, and manufactures biologic drugs for several prevalent, worldwide diseases—many of which currently lack any effective treatments. The company's unique drug development and manufacturing platform offers the potential to transform the biologics industry through increased speed, mass-market scale, and exponentially lower costs than current approaches. Lumen's clinical pipeline includes investigational biologic drugs for C. difficile infection, Covid-19, norovirus, and traveler's diarrhea. For more information, visit: www.lumen.bio.
Media Contact:
media@lumenbio.com
SOURCE Lumen Bioscience
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.